Clinicoepidemiological study of dengue positive patients admitted to tertiary care hospitals in the Burdwan district, using molecular seroprofiling and enzyme linked immunosorbent assays of cytokines and chemokines
DOI:
https://doi.org/10.3126/ajms.v14i5.52001Keywords:
Dengue; ELISA; Real-time-PCR; Serotype; DENG-3; Interferon-gamma; Cytokines and Chemokines; Co-morbiditesAbstract
Background: The World Health Organization views dengue fever as a significant worldwide public health threat in the tropics and subtropics. Dengue virus has four serotypes, DENG 1 to 4, which were responsible for outbreaks that occurred in other parts of the world from the 1980s until now.
Aims and Objectives: Clinical manifestations and molecular and serological studies help determine the inflammatory response events associated with dengue severity. This study aimed to define the profiles of some cytokines and chemokines, as well as their molecular serotyping.
Materials and Methods: Blood serum samples are collected, followed by serodiagnosis (NS1 and IgM) through ELISA, molecular serotyping detection of dengue by real-time PCR through SyBr green, and an immunological study of cytokines tumor necrosis factor-alpha and interferon-gamma (IFN-γ) on mother-hand chemokines CCL26 and MCP1 by ELISA. Statistical analysis was performed by SPSS (version 22).
Results: The study examined 70 dengue seropositive samples, of which five were NS1 positive and 55 were IgM positive. After accounting for comorbidities and patients’ demographic classifications, the 21–30 age group has a maximum positivity of 30%. The mean concentration level of IFN-γ is elevated at 1544.438 pg/mL.
Conclusion: Dengue-positive patients have a high ischemic heart disease rate, among other diseases. An elevated circulating level of osteopetrosis may cause cancer, tuberculosis, and other serious diseases. In immunological aspects, IFN-γ elevation can be used to predict the severity of dengue infection.
Downloads
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Asian Journal of Medical Sciences
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- The journal holds copyright and publishes the work under a Creative Commons CC-BY-NC license that permits use, distribution and reprduction in any medium, provided the original work is properly cited and is not used for commercial purposes. The journal should be recognised as the original publisher of this work.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).